IRIS
PALAZZUOLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.418
EU - Europa 4.409
AS - Asia 3.223
SA - Sud America 596
AF - Africa 137
OC - Oceania 11
Totale 16.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.334
RU - Federazione Russa 1.191
CN - Cina 1.077
SG - Singapore 945
GB - Regno Unito 930
IE - Irlanda 555
BR - Brasile 478
VN - Vietnam 435
IT - Italia 319
SE - Svezia 310
HK - Hong Kong 283
UA - Ucraina 278
DE - Germania 251
FR - Francia 223
FI - Finlandia 166
KR - Corea 144
IN - India 92
ZA - Sudafrica 61
AR - Argentina 53
BD - Bangladesh 49
MX - Messico 37
TR - Turchia 35
CA - Canada 31
IQ - Iraq 29
NL - Olanda 29
ES - Italia 25
BE - Belgio 23
PL - Polonia 23
JP - Giappone 22
CZ - Repubblica Ceca 20
KE - Kenya 19
PK - Pakistan 14
CO - Colombia 13
EC - Ecuador 13
UZ - Uzbekistan 13
CL - Cile 12
NG - Nigeria 12
SA - Arabia Saudita 12
MA - Marocco 11
ID - Indonesia 10
PE - Perù 10
AU - Australia 9
NP - Nepal 9
PY - Paraguay 9
CI - Costa d'Avorio 8
GR - Grecia 7
IL - Israele 7
AT - Austria 6
BG - Bulgaria 6
DK - Danimarca 6
EG - Egitto 6
LT - Lituania 6
VE - Venezuela 6
AL - Albania 5
AZ - Azerbaigian 5
DZ - Algeria 5
MY - Malesia 5
PH - Filippine 5
PT - Portogallo 5
RO - Romania 5
IR - Iran 4
JO - Giordania 4
PS - Palestinian Territory 4
TN - Tunisia 4
BY - Bielorussia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
GE - Georgia 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
PA - Panama 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
BO - Bolivia 2
BW - Botswana 2
CH - Svizzera 2
IM - Isola di Man 2
JM - Giamaica 2
KH - Cambogia 2
LV - Lettonia 2
LY - Libia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
RS - Serbia 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
BF - Burkina Faso 1
DM - Dominica 1
ET - Etiopia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MR - Mauritania 1
Totale 16.789
Salva come PNG Salva come JPEG
Città #
Dallas 3.321
Southend 746
Dublin 549
Singapore 548
Fairfield 535
Ashburn 492
Moscow 369
Chandler 311
Woodbridge 278
Hong Kong 267
Beijing 266
Ann Arbor 264
Houston 234
Santa Clara 229
San Jose 225
Jacksonville 220
Seattle 216
Wilmington 214
Hefei 209
Cambridge 172
Seoul 141
Dong Ket 117
Los Angeles 111
Council Bluffs 100
The Dalles 98
New York 92
Princeton 92
Ho Chi Minh City 90
Hanoi 86
Munich 80
Nanjing 77
Siena 77
Lauterbourg 70
Helsinki 65
Johannesburg 58
Turku 49
Shanghai 48
São Paulo 48
Dearborn 44
Boardman 43
Changchun 41
Buffalo 40
San Nicola la Strada 37
Orem 32
London 30
Denver 25
San Mateo 25
Bengaluru 24
Columbus 24
Brussels 23
Frankfurt am Main 23
Phoenix 23
Rio de Janeiro 22
Rome 21
Shenyang 21
Chicago 19
Düsseldorf 19
Lancaster 19
Redondo Beach 19
Tokyo 19
Milan 18
Warsaw 18
Chennai 17
Florence 17
Haiphong 17
Jiaxing 16
Kunming 16
Nanchang 16
Brooklyn 15
Changsha 15
Hebei 15
San Diego 15
Da Nang 14
Tianjin 14
Atlanta 13
Baghdad 13
Jinan 13
Manchester 13
Mexico City 12
San Francisco 12
Tashkent 12
Toronto 12
Belo Horizonte 11
Biên Hòa 11
Nairobi 11
Amsterdam 10
Brno 10
Guangzhou 10
Menlo Park 10
Portsmouth 10
Abuja 9
Barnet 9
Boston 9
Izmir 9
Mumbai 9
Málaga 9
New Delhi 9
Abidjan 8
Ankara 8
Brasília 8
Totale 12.250
Salva come PNG Salva come JPEG
Nome #
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 1.011
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 772
The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines 438
Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. 391
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 376
B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. 368
Sex-related differences in chronic heart failure 335
B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function 328
Natriuretic peptides in heart failure: where we are, where we are going. 307
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure 298
H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease 296
Myocardial 123I-metaiodobenzylguanidine imaging in hypertension and left ventricular hypertrophy 293
Quantitative evaluation of microvessels in Behcet's disease 288
Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance 279
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia 270
Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. 269
Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide 269
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 256
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 256
Prognostic significance of hyperuricemia in patients with acute heart failure 256
Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure 254
Comparison of neutrophil gelatinase-associated lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure 253
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial 250
The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions 234
Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy 232
Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management 230
Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function 224
The role of fibrosis and inflammation for response and outcome prediction in candidates to cardiac resynchronization therapy: is response the right answer? 223
Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application 217
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure 215
Definizione di pattern videocapillaroscopici (VCS) di normalità nel microcircolo cutaneo. Stratificazione secondo l'età 214
The role of natriuretic peptides for the diagnosis of left ventricular dysfunction 204
Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization 203
Natriuretic peptides and NGAL in heart failure: does a link exist? 200
Dyslipidemias and fibrinolysis. 192
Current therapeutic strategies in cardiorenal syndrome 191
Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection 189
Peptide natriuretico di tipo B ed ecocardiografia Doppler nella diagnosi di scompenso cardiaco: Metodiche alternative o complementari? [B-type natriuretic peptide and Doppler echocardiography in the diagnosis of heart failure: alternative or complementary tools?] 186
Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension 183
Heart failure: pathophysiology and clinical picture. 181
The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study 178
From gene mutations to biomechanical abnormalities and electrophysiological remodeling in hypertrophic cardiomyopathy: exploring the translational approach. 171
The potential role of natriuretic peptides in acute coronary syndrome stratification 170
A multidisciplinary approach in neurofibromatosis 1 169
Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? 166
Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries 153
Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients 153
Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction 148
Arterial hypertension and atrial fibrillation: Standard and advanced echocardiography from diagnosis to prognostication 147
Pulmonary congestion assessment in heart failure: traditional and new tools 142
Combined BNP and Echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection 140
Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure 139
Clinical impact of oral antidiabetic medications in heart failure patients 134
Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes 131
null 122
null 120
The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure 116
null 111
Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF 107
Additional value of Galectin-3 respect to BNP in acute heart failure patients with preserved ejection fraction 106
null 105
Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure 103
Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care 102
The role of fibrosis, inflammation, and congestion biomarkers for outcome prediction in candidates to cardiac resynchronization therapy: is “response” the right answer? 101
null 100
Effects of metolazone administration on congestion, diuretic response and renal function in patients with advanced heart failure 99
Usefulness of combined ultrasound assessment of E/e' ratio, pulmonary pressure, and cava vein status in patients with acute heart failure 98
Clinical impact of renal dysfunction in heart failure 96
Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities. 94
Cardio-renal syndrome revealed increased neurohormonal activity, tubular and myocardial damage respect to heart failure patients with preserved renal function 93
The predictive value of plasma biomarkers in discharged heart failure patients: the role of plasma BNP 90
Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF 83
Chronotropic incompetence across heart failure categories 82
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy 81
Integrated Cardiorespiratory Rehabilitation and Its Impact on Cardio-Renal-Metabolic Profile After Cardiac Surgery 78
Right ventricular dysfunction in chronic heart failure: Clinical laboratory and echocardiographic characteristics. (the RIVED-CHF registry) 77
Heart failure outpatient clinics resources in Italy: a viewpoint of Italian Society of Cardiology organization 77
The relevance of specific heart failure outpatient programs in the COVID era: An appropriate model for every disease 74
Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update 71
Continuous versus intermittent loop diuretics infusion dosing in acute heart failure: effects on renal function, outcome and BNP levels 69
Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature 69
Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction 68
Different neurohormonal and inflammatory pattern in acute CRS respect to AHF patients with preserved renal function 63
Contemporary assessment of lung ultrasound, BNP and echocardiography for outcome prediction in patients with decompensated heart failure 60
Contemporary assessment of lung ultrasound, bnp and echocardiography predicts outcome in patients with acute heart failure independently to systolic dysfunction 54
Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence 52
Combination Between Biomarkers and Echocardiographic Data for Prediction of Left Ventricular Reverse Remodelling in Cardiac Resynchronization Therapy 52
Resistant hypertension: An overview 52
The assessment, interpretation and implementation of lung ultrasound examinations in Heart Failure: Current evidence and gaps in knowledge 52
The Role of Lung Ultrasound Scan in Different Heart Failure Scenarios: Current Applications and Lacks of Evidences 51
The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction 44
Transient versus persistent worsening renal function during hospitalization in acute heart failure: different phenotypes for different outcome 42
Multi-biomarkers laboratory strategy for outcome prediction in patients with severe systolic dysfunction submitted to CRT 35
Dynamic variation of renal function and novel or old HF biomarkers (ST2, Galectin 3, NT-proBNP) and response to cardiac resynchronization therapy (CRT) 35
Plasma Neuthrophil Gelatinase associated Lipocalin (NGAL) predict worsening renal function and outcome in patients with acute decompensated heart failure 28
Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated 16
Incidental cardiac mass: Differential diagnosis, clinical approach and review of the literature,Massa cardiaca incidentale: Diagnosi differenziale, approccio clinico e revisione della letteratura 9
Totale 17.009
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.739
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021345 0 0 0 0 0 0 0 0 0 98 77 170
2021/2022648 34 70 31 70 60 24 28 24 38 72 65 132
2022/20231.016 61 90 136 131 112 189 24 80 86 18 32 57
2023/2024873 46 21 96 41 19 224 303 21 5 23 12 62
2024/20252.142 41 70 136 106 232 166 113 104 168 101 270 635
2025/20268.165 481 1.666 2.226 899 1.239 249 654 157 201 393 0 0
Totale 17.009